Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer

Completed · Phase 2

Conditions studied: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific

In brief

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill metastatic cancer cells. Interferon alfa may interfere with the growth of the cancer cells. Combining interleukin-2 and interferon alfa may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of interleukin-2 plus interferon alfa in treating adults with metastatic cancer.

Key facts

Study ID

NCT00002504

Run by

Hoag Memorial Hospital Presbyterian

Starts

1992-08-01

Expected to finish

1999-02-01

Last updated by the study team

2011-05-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Hoag Memorial Hospital Presbyterian — Newport Beach, California, United States
• Bloomington Hospital — Bloomington, Indiana, United States
• St. Vincent Hospital and Health Care Center Research Department — Indianapolis, Indiana, United States
• Bergan Mercy Medical Center — Omaha, Nebraska, United States
• Baptist Regional Cancer Center - Knoxville — Knoxville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.